These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32473188)

  • 1. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.
    Sánchez-Félix M; Burke M; Chen HH; Patterson C; Mittal S
    Adv Drug Deliv Rev; 2020 Dec; 167():66-77. PubMed ID: 32473188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics.
    Collins DS; Sánchez-Félix M; Badkar AV; Mrsny R
    J Control Release; 2020 May; 321():475-482. PubMed ID: 32105759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
    Bittner B; Richter W; Schmidt J
    BioDrugs; 2018 Oct; 32(5):425-440. PubMed ID: 30043229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point.
    Zou P
    AAPS J; 2023 Mar; 25(3):31. PubMed ID: 36959523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements.
    Badkar AV; Gandhi RB; Davis SP; LaBarre MJ
    Drug Des Devel Ther; 2021; 15():159-170. PubMed ID: 33469268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
    Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ
    J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.
    Collins DS; Kourtis LC; Thyagarajapuram NR; Sirkar R; Kapur S; Harrison MW; Bryan DJ; Jones GB; Wright JM
    Pharm Res; 2017 Oct; 34(10):2000-2011. PubMed ID: 28707164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components.
    Kinnunen HM; Sharma V; Contreras-Rojas LR; Yu Y; Alleman C; Sreedhara A; Fischer S; Khawli L; Yohe ST; Bumbaca D; Patapoff TW; Daugherty AL; Mrsny RJ
    J Control Release; 2015 Sep; 214():94-102. PubMed ID: 26210441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.
    Zhuang Y; de Vries DE; Marciniak SJ; Liu H; Zhou H; Davis HM; Leon F; Raible D; Xu Z
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):570-576. PubMed ID: 28052588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous delivery of biotherapeutics: challenges at the injection site.
    Sequeira JAD; Santos AC; Serra J; Estevens C; Seiça R; Veiga F; Ribeiro AJ
    Expert Opin Drug Deliv; 2019 Feb; 16(2):143-151. PubMed ID: 30632401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics.
    Fathallah AM; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):301-6. PubMed ID: 25411114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous absorption of biotherapeutics: knowns and unknowns.
    Richter WF; Jacobsen B
    Drug Metab Dispos; 2014 Nov; 42(11):1881-9. PubMed ID: 25100673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.
    Curreri AM; Kim J; Dunne M; Angsantikul P; Goetz M; Gao Y; Mitragotri S
    Adv Sci (Weinh); 2023 Mar; 10(7):e2205389. PubMed ID: 36642846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous administration of biotherapeutics: current experience in animal models.
    McDonald TA; Zepeda ML; Tomlinson MJ; Bee WH; Ivens IA
    Curr Opin Mol Ther; 2010 Aug; 12(4):461-70. PubMed ID: 20677097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins.
    Kagan L
    Drug Metab Dispos; 2014 Nov; 42(11):1890-905. PubMed ID: 25122564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides.
    Datta-Mannan A
    Drug Metab Dispos; 2019 Oct; 47(10):1100-1110. PubMed ID: 31043438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation.
    Schweizer D; Vostiar I; Heier A; Serno T; Schoenhammer K; Jahn M; Jones S; Piequet A; Beerli C; Gram H; Goepferich A
    J Control Release; 2013 Dec; 172(3):975-82. PubMed ID: 24140353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.
    Haraya K; Tachibana T
    Clin Pharmacokinet; 2021 Jan; 60(1):111-120. PubMed ID: 32779124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
    Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
    AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.